[5-(ethylthio)-2-phenyl-1,3-oxazol-4-yl](triphenyl)phosphonium iodide | 76621-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [5-(ethylthio)-2-phenyl-1,3-oxazol-4-yl](triphenyl)phosphonium iodide
• 英文别名: [5-ethylsulfanyl-2-phenyl-1,3-oxazol-4-yl]triphenylphosphonium iodide；(5-Ethylsulfanyl-2-phenyl-1,3-oxazol-4-yl)-triphenylphosphanium;iodide
• CAS: 76621-79-9
• 化学式: C₂₉H₂₅NOPS*I
• 分子量: 593.468
• InChiKey: RJUYAAJGFQIVQL-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  51.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [5-(ethylthio)-2-phenyl-1,3-oxazol-4-yl](triphenyl)phosphonium iodide 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以76%的产率得到5-Ethylsulfanyl-2-phenyl-oxazole
  参考文献：
  名称：

  Brovarets, V. S.; Lobanov, O.P.; Drach, B. S., Journal of general chemistry of the USSR, 1983, vol. 53, # 9, p. 1819 - 1823

  摘要：

  DOI：
• 作为产物：
  描述：

  1-benzoylamino-2,2-dichloroethenyltriphenylphosphonium chloride 在 sodium hydrogensulfide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 [5-(ethylthio)-2-phenyl-1,3-oxazol-4-yl](triphenyl)phosphonium iodide
  参考文献：
  名称：

  Lobanov, O. P.; Martynyuk, A. P.; Drach, B. S., Journal of general chemistry of the USSR, 1980, vol. 50, p. 1816 - 1824

  摘要：

  DOI：

文献信息

• Evaluation of Anticancer Activity of 1,3‐Oxazol‐4‐ylphosphonium Salts <i>in Vitro</i>
  作者：Mykhailo Brusnakov、Olexandr Golovchenko、Yevheniia Velihina、Oleksandr Liavynets、Victor Zhirnov、Volodymyr Brovarets

  DOI：10.1002/cmdc.202200319

  日期：2022.10.19

  Excellent anticancer activity of 1,3-oxazol-4-ylphosphonium salts has been demonstrated in a total panel of NCI tumor cell lines. The average values of the antitumor activity parameters of the most potent derivatives ranged from 0.3–1.1 μM (GI50), 1.2–2.5 μM (TGI), and 5–6 μM (LC50). The cytotoxicity vector of the compound 9 showed a high positive correlation with standard antitumor agents that induce

  1,3-恶唑-4-基鏻盐的优异抗癌活性已在所有 NCI 肿瘤细胞系中得到证实。最有效的衍生物的抗肿瘤活性参数的平均值范围为0.3–1.1 μM (GI 50 )、1.2–2.5 μM (TGI) 和5–6 μM (LC 50 )。化合物9的细胞毒性载体与标准抗肿瘤药物呈高度正相关，标准抗肿瘤药物通过半胱天冬酶依赖性内在线粒体途径诱导细胞凋亡。可以推荐最活跃的化合物（ 9、1和4 ）在其基础上进一步深入研究和合成具有抗肿瘤活性的新的更有效的衍生物。
• In silico and in vitro studies of a number PILs as new antibacterials against MDR clinical isolate <i>Acinetobacter baumannii</i>
  作者：Maria M. Trush、Vasyl Kovalishyn、Diana Hodyna、Olexandr V. Golovchenko、Svitlana Chumachenko、Igor V. Tetko、Volodymyr S. Brovarets、Larysa Metelytsia

  DOI：10.1111/cbdd.13678

  日期：2020.6

  AbstractQSAR analysis of a set of previously synthesized phosphonium ionic liquids (PILs) tested against Gram‐negative multidrug‐resistant clinical isolate Acinetobacter baumannii was done using the Online Chemical Modeling Environment (OCHEM). To overcome the problem of overfitting due to descriptor selection, fivefold cross‐validation with variable selection in each step of the model development was applied. The predictive ability of the classification models was tested by cross‐validation, giving balanced accuracies (BA) of 76%–82%. The validation of the models using an external test set proved that the models can be used to predict the activity of newly designed compounds with a reasonable accuracy within the applicability domain (BA = 83%–89%). The models were applied to screen a virtual chemical library with expected activity of compounds against MDR Acinetobacter baumannii. The eighteen most promising compounds were identified, synthesized, and tested. Biological testing of compounds was performed using the disk diffusion method in Mueller‐Hinton agar. All tested molecules demonstrated high anti‐A. baumannii activity and different toxicity levels. The developed classification SAR models are freely available online at http://ochem.eu/article/113921 and could be used by scientists for design of new more effective antibiotics.
• COMPOSITIONS AND METHODS FOR CANCER THERAPY
  申请人：SCHULTZ Michael K.

  公开号：US20150366884A1

  公开（公告）日：2015-12-24

  The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.